REFRACTORY MYELODYSPLASTIC/MYELOPROLIFERATIVE NEOPLASM
Clinical trials for REFRACTORY MYELODYSPLASTIC/MYELOPROLIFERATIVE NEOPLASM explained in plain language.
Never miss a new study
Get alerted when new REFRACTORY MYELODYSPLASTIC/MYELOPROLIFERATIVE NEOPLASM trials appear
Sign up with your email to follow new studies for REFRACTORY MYELODYSPLASTIC/MYELOPROLIFERATIVE NEOPLASM, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New pill targets hard-to-treat blood cancers in early trial
Disease control Recruiting nowThis early-stage study tests a new pill called onvansertib for people with specific blood cancers (CMML or MDS/MPN) that have returned or stopped responding to other treatments. The drug works by blocking a protein that helps cancer cells grow. The main goals are to find the best…
Matched conditions: REFRACTORY MYELODYSPLASTIC/MYELOPROLIFERATIVE NEOPLASM
Phase: PHASE1 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated May 17, 2026 06:48 UTC
-
New Triple-Drug cocktail targets tough leukemia mutations
Disease control Recruiting nowThis study is for people with certain blood cancers (acute myeloid leukemia, chronic myelomonocytic leukemia, or high-risk myelodysplastic syndrome) that have a specific genetic change called a FLT3 mutation. The cancer has either come back or not responded to prior treatment. Th…
Matched conditions: REFRACTORY MYELODYSPLASTIC/MYELOPROLIFERATIVE NEOPLASM
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 15, 2026 11:56 UTC
-
New hope for rare blood cancers: drug combo trial launches
Disease control Recruiting nowThis study tests a new antibody drug (axatilimab) with or without a chemotherapy-like drug (azacitidine) in people with advanced blood cancers like MPN, MPN/MDS overlap, or high-risk CMML. The goal is to find the best dose and see if the combination can shrink or control the canc…
Matched conditions: REFRACTORY MYELODYSPLASTIC/MYELOPROLIFERATIVE NEOPLASM
Phase: PHASE1, PHASE2 • Sponsor: Uma Borate • Aim: Disease control
Last updated May 15, 2026 11:53 UTC